



JG07 Rec'd PCT/PTO 20 FEB 2002 Dkt 4-10-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/744,226
Filed: January 22, 2001
1st Inventor: O. OHARA
For: Novel G Protein Coupled Receptor and its DNA
Atty. Dkt. No. 2534 USOP

Art Unit: 1646
Examiner: tba
Allowed:
Batch:
Paper No.:

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

RECEIVED

APR 03 2002

TECH CENTER 1600/2900

Sir:

Applicants request that a corrected Filing Receipt be issued for the above-identified case correcting the title of the invention. Please rewrite the title of the invention to read as follows:

--NOVEL G PROTEIN COUPLED RECEPTOR AND ITS DNA--

A copy of the Filing Receipt is enclosed showing the correction.

If there are any questions, please call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: February 20, 2002

(847) 383-3372

(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Reg. No. 43,032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/744,226	01/22/2001	1646	1184	2534USOP	25	23	1

CONFIRMATION NO. 5358

23115
TAKEDA PHARMACEUTICALS NORTH AMERICA, INC
INTELLECTUAL PROPERTY DEPARTMENT
475 HALF DAY ROAD
SUITE 500
LINCOLNSHIRE, IL 60069

FILING RECEIPT



OC000000007324258

Date Mailed: 01/25/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Osamu Ohara, Chiba, JAPAN;
Takahiro Nagase, Chiba, JAPAN;
Nobuo Nomura, Chiba, JAPAN;
Shuji Hinuma, Ibaraki, JAPAN;
Ryo Fujii, Ibaraki, JAPAN;
Osamu Kitahara, Ibaraki, JAPAN;
Shinichi Mogi, Ibaraki, JAPAN;

RECEIVED

APR 03 2002

TECH CENTER 1600/2900

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP99/03909 07/22/1999


Foreign Applications

JAPAN 10/207579 07/23/1998
JAPAN 10/225060 08/07/1998
JAPAN 10/284328 06/10/1998

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No



Title

~~Novel g protein-conjugated receptor protein and dna thereof~~
 --Novel G. Protein Coupled Receptor and its DNA--

Preliminary Class

530

RECEIVED

APR 03 2002

TECH CENTER 1600/2900

**LICENSE FOR FOREIGN FILING UNDER
 Title 35, United States Code, Section 184
 Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.


This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/744,226
Filed: January 22, 2001
1st Inventor: O. OHARA
For: Novel G Protein Coupled Receptor and its DNA
Atty. Dkt. No. 2534 USOP

Art Unit: 1646
Examiner: tba
Allowed:
Batch:
Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EL 916493047 US

DATE IN: February 20, 2002

Itemized Papers/Items:

1. This certificate and a Return Receipt Postcard (2 pgs.)
2. Transmittal Form (1 pg. X 2)
3. Request to Correct Filing Receipt, and copy of Filing Receipt (3 pgs.)

RECEIVED

APR 03 2002


TECH CENTER 1600/2900

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:


Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231.

on this date, 2/20/02

Dated: 2/20/02


Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA



Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/744,226	
	Filing Date	January 22, 2001	
	First Named Inventor	O. OHARA	
	Group Art Unit	1646	
	Examiner Name	tba	
Total Number of Pages in This Submission	7	Attorney Docket Number	2534

RECEIVED
APR 03 2002
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard. Certificate of Express Mailing Request to Correct Filing Receipt + copy of Filing Receipt
Remarks		The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mark Chao, Ph.D., JD, Reg. No. 37,293
Signature	
Date	2/20/02

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class EXPRESS mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 2/20/02			
Typed or printed name	Gail L. Winokur		
Signature		Date	2/20/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail # 9649304745